
ADC Therapeutics SA
NYSE:ADCT

Intrinsic Value
ADC Therapeutics SA is a clinical-stage biotechnology company. [ Read More ]
The intrinsic value of one
ADCT
stock under the Base Case scenario is
0.58
USD.
Compared to the current market price of 0.83 USD,
ADC Therapeutics SA
is
Overvalued by 31%.


Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.
Sign up
to access ADC Therapeutics SA's intrinsic value history.
No restrictions, no limits.
All stocks, all tools.
There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.
DCF Value
Discounted Cash Flow
Fundamental Analysis
Balance Sheet Decomposition
ADC Therapeutics SA
Current Assets | 413m |
Cash & Short-Term Investments | 348m |
Receivables | 23.9m |
Other Current Assets | 41.4m |
Non-Current Assets | 94.5m |
Long-Term Investments | 28.3m |
PP&E | 16.4m |
Intangibles | 13.5m |
Other Non-Current Assets | 36.3m |
Current Liabilities | 80.6m |
Accounts Payable | 11.7m |
Other Current Liabilities | 68.9m |
Non-Current Liabilities | 435m |
Long-Term Debt | 407m |
Other Non-Current Liabilities | 27.9m |
ADCT Profitability Score
Profitability Due Diligence
ADC Therapeutics SA's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Score
ADC Therapeutics SA's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
ADCT Solvency Score
Solvency Due Diligence
ADC Therapeutics SA's solvency score is 30/100. The higher the solvency score, the more solvent the company is.

Score
ADC Therapeutics SA's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADCT Price Targets Summary
ADC Therapeutics SA
According to Wall Street analysts, the average 1-year price target for
ADCT
is 8.17 USD
.
Shareholder Return
ADCT Price
ADC Therapeutics SA
Average Annual Return | -15.11% |
Standard Deviation of Annual Returns | 33.63% |
Max Drawdown | -99% |
Market Capitalization | 66.9m USD |
Shares Outstanding | 80 642 527 |
Percentage of Shares Shorted | 11.87% |
Company Profile


Country
Industry
Market Cap
Dividend Yield
Description
ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
Contact
IPO
Employees
Officers
The intrinsic value of one
ADCT
stock under the Base Case scenario is
0.58
USD.
Compared to the current market price of 0.83 USD,
ADC Therapeutics SA
is
Overvalued by 31%.